Dual Immunotherapy Edges Out Pembrolizumab in Cost-Effectiveness for MSI-High Colorectal Cancer
A new cost-effectiveness analysis finds nivolumab plus ipilimumab may offer greater quality-adjusted life years at lower cost than pembrolizumab as ...
A new cost-effectiveness analysis finds nivolumab plus ipilimumab may offer greater quality-adjusted life years at lower cost than pembrolizumab as ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine